Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from pharmacy benefit managers. These https://umariyec583665.ambien-blog.com/48916844/the-vyndamax-faces-is-dealing-with-pharmacy-benefit-manager-challenges-the-look-at-reimbursement-disputes